Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 14/20 | 0.47 |
| ▸ | CTSK | P43235 | 14/20 | 0.47 |
| ▸ | CTSS | P25774 | 13/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476560 | 0.90 | CTSK (0.57) | CTSLCTSKCTSS | |
| SCHEMBL6476759 | 0.88 | CTSK (0.45) | CTSLCTSKCTSSCNR2 | |
| SCHEMBL6477161 | 0.82 | CTSK (0.47) | CTSLCTSKCTSSCNR2 | |
| SCHEMBL6486342 | 0.78 | CTSL (0.46) | CTSLCTSKCTSS | |
| SCHEMBL6475485 | 0.77 | CTSK (0.50) | CTSLCTSKCTSS | |
| SCHEMBL6474867 | 0.75 | CTSK (0.60) | CTSLCTSKCTSS | |
| SCHEMBL6597915 | 0.75 | CTSK (0.60) | CTSLCTSKCTSS | |
| SCHEMBL6485355 | 0.72 | CTSK (0.56) | CTSLCTSKCTSS | |
| SCHEMBL6484184 | 0.72 | CTSK (0.47) | CTSLCTSKCTSSRAB9AALDH1A1 | |
| SCHEMBL6484312 | 0.71 | CTSK (0.57) | CTSLCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSL 11/4885CTSK 4/4885CTSS 1/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSL 11/4885CTSK 4/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.